Chime Biologics Announces Strategic Collaboration with Beijing Libang Pharmaceutical on Global Blinatumomab Biosimilar Program

December 10, 2025, Wuhan, China - Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced strategic collaboration with Beijing Libang Pharmaceutical Co., Ltd. on the development, manufacturing, and overseas licensing and financing of a blinatumomab biosimilar. Blinatumomab is a CD3–CD19 bispecific T-cell engager (BiTE) indicated for the treatment of hematological malignancies.

Dr. Chunhui Di, Deputy General Manager of Beijing Libang Pharmaceutical Co., Ltd.; Dr. Yun Qin, Deputy General Manager of Xi’an Lipont Enterprise Union Management Co., Ltd.; Dr. Jimmy Wei, CEO of Chime Biologics; and Dr. Peter Pang, General Manager of the Chime China Innovation Hub, attended the signing ceremony.

Blinatumomab represents one of the most complex and advanced therapeutic modalities in oncology today, highlighting Chime Biologics’ leading CMC capabilities in the development and manufacturing of complex molecules, including bispecific T-cell engagers. This collaboration also creates strong synergies with multiple global biosimilar programs that Chime Biologics has launched throughout the year, further strengthening its integrated capabilities in global biosimilar development.

Under the agreement, Chime Biologics will provide end-to-end development and manufacturing services, spanning from CMC development to overseas licensing and financing support, as well as global commercial manufacturing. The partnership leverages the historic opportunities arising from regulatory reforms in the U.S. and Europe that allow biosimilars to waive Phase III clinical trials, enabling Chinese biopharmaceutical companies to enter global markets more efficiently. This collaboration further demonstrates Chime Biologics’ extensive experience in late-stage and commercial-phase programs, particularly in supporting partners to develop high-quality, globally compliant, and affordable biosimilars that benefit patients worldwide.

Dr. Chunhui Di, Deputy General Manager of Beijing Libang Pharmaceutical Co., Ltd., commented: “Blinatumomab has brought breakthrough therapeutic hope to patients with hematologic malignancies, and the development of its biosimilar is of great significance. Chime Biologics’ deep expertise in complex molecule CMC and global commercialization is highly trusted and forms a strong complement to our innovation-driven R&D capabilities. This collaboration marks the beginning of a joint effort, and we look forward to leveraging Chime Biologics’ global service platform to bring this high-quality biologic to more countries and patients, jointly building a global ecosystem for biopharmaceutical innovation.”

Dr. Jimmy Wei, CEO of Chime Biologics, stated: “We are delighted to partner with Beijing Libang Pharmaceutical on this highly complex biosimilar program. As we continue to advance multiple global biosimilar projects this year, Chime Biologics’ international development and delivery capabilities are being consistently validated. Global demand for high-quality and affordable biosimilars is rapidly increasing, and regulatory reforms in the U.S. and Europe that enable Phase III clinical trial waivers for certain biosimilars are creating important opportunities for Chinese companies to compete internationally. We look forward to this collaboration generating strong synergies with our other global biosimilar programs and delivering higher-quality, more affordable biosimilars to partners and patients worldwide.”

About Beijing Libang Pharmaceutical Co., Ltd.
Founded on July 25, 2017, Beijing Libang Pharmaceutical Co., Ltd. is a high-tech biotechnology company focused on the innovative R&D of biologics and antibody therapeutics. The company is located in the Zhongguancun Life Science Park and was jointly established by Xi’an Libang Pharmaceutical Group, one of China’s leading pharmaceutical enterprises, and Beijing Yishenghe Biotech, integrating strengths across drug R&D, manufacturing, and technological innovation.

About Chime Biologics

Chime Biologics is a leading global CDMO, focused on ensuring our customers' success in delivering innovative biologic medicines to patients across the world. Chime Biologics can support customers end to end, from pre-clinical support and cell line development through to clinical and commercial manufacturing of drug substance and drug product. Employing our innovative and state-of-the-art development and manufacturing capabilities and proven success in supporting our clients with their clinical and commercial authorizations across the globe, Chime Biologics is a true end-to-end solution provider for the biologics industry. With over 500 skilled employees, we share a common goal to make cutting-edge biomedicines affordable and accessible to patients worldwide, fulfilling our commitment to improving human health globally. For more information, please visit www.chimebiologics.com.